Business Context and Reporting Period
This Form 6-K filing by DBV Technologies S.A. covers the month of November 2019, specifically dated November 5, 2019. The company is a clinical-stage biopharmaceutical firm headquartered in Montrouge, France, with operations in the United States. It develops Viaskin, an investigational epicutaneous immunotherapy (EPIT) platform designed to treat food allergies and other immune diseases.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding a conference presentation and does not contain financial statements or quantitative performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document, as it does not contain comparative financial data.
Guidance, Outlook, and Management Commentary
- Conference Presentation: Kevin Trapp, Chief Commercial Officer, is scheduled to present at the Stifel 2019 Healthcare Conference in New York on November 20, 2019, at 8:00 am EST.
- Webcast Availability: A live webcast will be available on the company's Investor Relations website, with a replay accessible for 90 days.
- Pipeline Status: The company continues ongoing clinical trials for Viaskin Peanut and Viaskin Milk, preclinical development of Viaskin Egg, and a human proof-of-concept study for Viaskin Milk in treating Eosinophilic Esophagitis.
- Market Presence: Ordinary shares trade on Euronext Paris (Ticker: DBV), and ADSs trade on the Nasdaq Global Select Market (Ticker: DBVT).
Key Facts for Investor Verification
- Verify the date and time of the Stifel 2019 Healthcare Conference presentation (November 20, 2019, 8:00 am EST).
- Confirm the availability of the webcast replay on the official DBV Technologies Investor Relations website.
- Review the latest clinical trial progress for Viaskin Peanut and Viaskin Milk, as this filing only confirms ongoing status without specific data points.
- Check the Nasdaq ticker (DBVT) and Euronext ticker (DBV) for current trading status and share price.